Shots: The P-II study involves assessing Olamkicept (300/600mg, q2w, IV) vs PBO in 91 patients in a ratio (1:1:1) who had active UC with a full Mayo score ≥5, a […]readmore
Tags : Olamkicept
Latest Posts
Categories
Related Topics
AbbVie
Acceptance
Acquire
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Boehringer Ingelheim
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Lilly
Merck
Novartis
P-III
patients
Pfizer
receives
Regeneron
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
Treat
Treatment
US